Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Change in Receivables (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Change in Receivables for 16 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 8.03% to $4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Dec 2025, down 42.65% year-over-year, with the annual reading at $7.5 million for FY2025, 42.65% down from the prior year.
  • Change in Receivables hit $4.1 million in Q4 2025 for Vanda Pharmaceuticals, down from $5.6 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $9.1 million in Q2 2023 to a low of -$9.0 million in Q4 2021.
  • Historically, Change in Receivables has averaged $1.2 million across 5 years, with a median of $2.0 million in 2021.
  • Biggest YoY gain for Change in Receivables was 662.42% in 2023; the steepest drop was 829.85% in 2023.
  • Year by year, Change in Receivables stood at -$9.0 million in 2021, then skyrocketed by 145.16% to $4.1 million in 2022, then rose by 18.79% to $4.8 million in 2023, then fell by 8.37% to $4.4 million in 2024, then fell by 8.03% to $4.1 million in 2025.
  • Business Quant data shows Change in Receivables for VNDA at $4.1 million in Q4 2025, $5.6 million in Q3 2025, and $353000.0 in Q2 2025.